Emerging Markets Report: A Pretty Good Month
ORLANDO, Fla., Dec. 23, 2019 (GLOBE NEWSWIRE) -- As the holidays roll into November and December many companies go quietly into the New Year, eschewing news releases or large scale investor communication. That has definitely not been the case for Hoth Therapeutics, Inc. (NASDAQ: HOTH) - a biopharmaceutical company focused on developing new generation therapies for a wide variety of dermatological disorders.
And the news from Hoth has been compelling. A simple review of the Hoth news feed shows a litany of major accomplishments over the past month or so including significant collaborations with major research partners and presentations at leading investor conferences. The simultaneous timing of the two is also worth noting. Hoth is making news with a lot of new eyes on the story.
As the company presented at Benchmark’s 8th Annual Discovery 1x1 Conference, the Investor Summit, and the LD Micro Main Event in recent weeks it was also adding to its corporate story and business plan.
New investors and prospective investors tuning into Hoth are seeing a company aggressively pursuing partnerships and future market opportunities. Since the Benchmark event in November alone, Hoth has announced the following accomplishments:
-- Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression -- Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma -- Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy
These are exceptional opportunities for Hoth Therapeutics to add to its potential portfolio of drugs and therapies with respected and established research partners. And with the company having hit the road in a big way, it appears that Hoth picked a pretty good time to have a pretty good month.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company’s proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid $92,500 on behalf of Hoth Therapeutics, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php